Business
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
WATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing
About this update from Eyepoint, Inc.
[{"type":"text","content":"WATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Jay S. Duker, M.D., President and Chief Executive of EyePoint Pharmaceuticals will present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference: Company OverviewDate: Wednesday, August 16th, 2023Time: Available on-demand at 7:00 a.m. ET Sustained Treatment for Wet AMD Panel DiscussionDate: Wednesday, August 16th, 2023Time: 11:00 a.m. ET A live webcast and subsequent archived replay of the panel and the on-demand company overview may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event. About EyePoint Pharmaceuticals EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit www.eyepointpharma.com. Investors:Christina TartagliaStern IRDirect: [email protected] Media ContactAmy PhillipsGreen Room CommunicationsDirect: [email protected] \nSource: EyePoint Pharmaceuticals, Inc.","length":4455,"tagName":"div"}]